- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill
- Liraglutide - ALZFORUM
Background Liraglutide is an analog of glucagon-like peptide 1 GLP-1 is a hormone that is produced in the gut and activates receptors in the gut, liver, and pancreas to control blood-sugar levels and reduce insulin resistance Liraglutide and related GLP-1 mimetics cause body weight loss and reduce the risk of cardiovascular events, stroke, and dementia in people with diabetes
- Semaglutide as a possible therapy for healthy aging: Targeting the . . .
Ortiz GU, de Freitas EC Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging Ageing Res Rev 2024 Dec;102:102582 Epub 2024 Nov 14 PubMed
- NT-0796 | ALZFORUM
In diet-induced obesity in these mice, NT-0796 caused weight loss as potently as did the GLP1 inhibitor semaglutide, and improved markers of cardiovascular risk (Thornton et al , 2024)
- Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its . . .
Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats J Chromatogr B Analyt Technol Biomed Life Sci 2023 Apr 15;1221:123688 Epub 2023 Mar 22 PubMed
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
- Protocol for a double-blind placebo-controlled randomised controlled . . .
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults
- Dapagliflozin - ALZFORUM
Type 2 diabetes is a risk factor for developing dementia, and people with Alzheimer’s disease display signs of insulin resistance in the brain These findings have spurred testing of multiple classes of diabetes drug for the treatment or prevention of AD (for example, see nasal insulin, pioglitazone, metformin, liraglutide and semaglutide)
|